FOR IMMEDIATE RELEASE — Phoenix, Oct. 12, 2017 (GLOBE NEWSWIRE) — / The “Introduction to Disruptive Agricultural Solutions” events that BioNovelus (OTC Pink: ONOV) began co-hosting in Guatemala in the summer are continuing with great success. The well-attended educational series has been organized in collaboration with Chamber of Commerce of Guatemala. The events aim to […]
FOR IMMEDIATE RELEASE — Phoenix, Oct. 12, 2017 (GLOBE NEWSWIRE) — / The “Introduction to Disruptive Agricultural Solutions” events that BioNovelus (OTC Pink: ONOV) began co-hosting in Guatemala in the summer are continuing with great success.
The well-attended educational series has been organized in collaboration with Chamber of Commerce of Guatemala. The events aim to bring information about BioNovelus’ disruptive eco-friendly CR-10 phytosanitary management system to producers and shippers in Central America.
“We feel our products are revolutionary,” says Jean Ekobo, President and CEO of BioNovelus, Inc. “We believe the potential applications are unlike what has gone before. We want to assist the people who will be using the product know exactly what to do with it for maximum efficacy. While a grassroots approach, we feel we need to be really hands on in order to be certain people fully understand the power of CR-10 and how they can best use it.”
The first presentation was held early in July at the Chamber of Commerce of Guatemala City. It was a great success. The two-hour workshop was facilitated by agronomic engineer Elmer Nij Reyes, who is in charge of CR-10 agricultural testing in Central America, and Jean Ekobo, BioNovelus CEO and Founder.
The second presentation was given to 70 people in Guatemala City on September 27. The third was in Quetzaltenango, Guatemala, a region specialized in farming, on September 29 with 59 attendees.
Among those attending were fruit and vegetable producers, coffee growers, large exporters of fruits and vegetables, agro-researchers from a prestigious Guatemalan university, and representatives from the Ministry of Agriculture.
These workshops are a welcome opportunity for BioNovelus to introduce the CR-10 System to the farmers, food packers, and exporters that need it most by showing concrete results and increasing visibility for sales. We previously announced the commercialization of CR-10 has begun in earnest. Our first contract sale was over $100,000.
BioNovelus is a bioscience company that honors the environment with innovative, cost-effective, and disruptive technology-based solutions to crop protection, food security, and health challenges.
About CR-10 Biofungicide
CR-10 Biofungicide is a proven, biodegradable, non-toxic solution that kills bacteria, fungi, and spores rapidly, safely and effectively. It is a new generation of biofungicide with a unique mode of action. BioNovelus management believes that CR-10 has a broad range of uses in crop protection before harvest.
This news release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for the fiscal year 2017 and beyond could differ materially from the Company’s current expectations. Forward-looking statements are identified by words such as “anticipates,” “projects,” “expects,” “plans,” “intends,” “believes,” “estimates,” “targets,” and other similar expressions that indicate trends and future events.
Factors that could cause the Company’s results to differ materially from forward-looking statements regarding the success of the workshops and efficacy of the crop restoration and results of CR-10 include the lack of capital needed to complete testing, the lack of experience with pursuing approval of this product and modifications and receipt of information that may be demanded by the registration of the CR-10 formula and the delays in the various government approval processes unrelated to the product itself. Factors that could cause lower turn-out in the future include the cities we select to have our workshops and the interest in alternatives to existing products, rates of success in CR-10 eradication of fungi and bacteria include the method and timing of applications of CR-10, the impact of the strength of fungi and bacteria contamination, and other environmental conditions resulting in re-infection. Factors that may impact Guatemalan acceptance of our product include the compatibility with other chemical products.
There is no assurance of when registrations in Guatemala will be obtained for CR-10 Biofungicide and various applications as several field trials are still in progress. There is no assurance that the coffee rust application or any other crop protection or post-harvest protection applications will prove commercially viable. There is no assurance that any transaction will be done with Guatemalan distributors.
Factors that could cause the Company’s results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company’s products and services, general business and economic conditions beyond the Company’s control the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, compatibility with other chemical products, the application of the products, and the Company’s success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements because of new information, since these statements may no longer be accurate or timely.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
— 30 —
CONTACT: Media contact: Nathalie Ekobo, Marketing & Communications Director BioNovelus, Inc. +1 888-924-6668 ext.1 NEkobo@BioNovelus.com Investor Relations: Anthony J. Parkinson, Chief Information Officer BioNovelus, Inc. +1 888-924-6668 ext.3 AParkinson@BioNovelus.com
Source: Health Care